Pharma Earnings Calls Reveal US/EU Trump Divide
Executive Summary
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.
You may also be interested in...
Cancer Programs Critical For 'New AstraZeneca' As Price Pressure, Regulatory Changes Loom In 2017
CEO discussed oncology programs crucial to AstraZeneca’s future and was upbeat on US pricing pressure and Brexit as he insisted the company was "rapidly approaching a return to growth."
Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear
Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.
Pfizer-Allergan Merger: The End Is Nigh
The end of Pfizer Inc.'s $160bn merger with Allergan PLC was nearly official late on April 5 after the US Treasury Department issued new rules endorsed by President Barack Obama to prevent tax inversion deals, leading analysts and industry observers to declare the "PfizerGan" transaction unlikely.